FDCDDQ
NRIX icon

Federation des caisses Desjardins du Quebec’s Nurix Therapeutics NRIX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.1K Buy
2,590
+1,000
+63% +$16.6K ﹤0.01% 1923
2025
Q4 		$30.2K Hold
1,590
– – ﹤0.01% 1952
2025
Q3 		$14.7K Buy
1,590
+800
+101% +$8.31K ﹤0.01% 2123
2025
Q2 		$9K Hold
790
– – ﹤0.01% 2071
2025
Q1 		$9.38K Buy
790
+500
+172% +$8.36K ﹤0.01% 1982
2024
Q4 		$5.46K Sell
290
-700
-71% -$16K ﹤0.01% 2057
2024
Q3 		$22.2K Sell
990
-700
-41% -$15.9K ﹤0.01% 1634
2024
Q2 		$35.3K Buy
1,690
+490
+41% +$7.63K ﹤0.01% 1468
2024
Q1 		$17.6K Hold
1,200
– – ﹤0.01% 1675
2023
Q4 		$12.4K Hold
1,200
– – ﹤0.01% 1702
2023
Q3 		$9.43K Hold
1,200
– – ﹤0.01% 1773
2023
Q2 		$12K Buy
1,200
+700
+140% +$7.14K ﹤0.01% 1703
2023
Q1 		$4.44K Buy
+500
New +$5.21K ﹤0.01% 1939

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's NRIX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec increased its Nurix Therapeutics (NRIX) stake by 63% in Q1 2026, buying an estimated $16.6K and bringing the position to 2,590 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

Federation des caisses Desjardins du Quebec first reported a position in NRIX in Q1 2023 and has held it in 13 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 2,590 shares of Nurix Therapeutics worth $40.1K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec bought 1,000 Nurix Therapeutics shares in Q1 2026, an estimated $16.6K.
  • Nurix Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #1923 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.